Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Pharma-Bio Serv did not have earnings to cover the interest expense.
Pharma-Bio Serv's debt to revenue ratio for the quarter that ended in Jul. 2026 was 0.00.
As of today, Pharma-Bio Serv's Altman Z-Score is 10.09.
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Pharma-Bio Serv has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Pharma-Bio Serv Financial Strength Related Terms
PBSV vs HCTI, BFRG, MGRX: Financial Strength Comparison
For the Health Information Services subindustry, Pharma-Bio Serv's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv Financial Strength vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Financial Strength distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Pharma-Bio Serv Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Pharma-Bio Serv's Debt to Revenue Ratio for the quarter that ended in Jul. 2026 is
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Pharma-Bio Serv has a Z-score of 10.09, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 10.09 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (PBSV) has a Financial Strength of 10 as of Jul. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Pharma-Bio Serv and its competitors. This is 25% above median its historical median of 8.00. Over the past decade, Pharma-Bio Serv's Financial Strength has ranged from 3.00 to 10.00.
Is Pharma-Bio Serv's Financial Strength too high?
Pharma-Bio Serv's current Financial Strength of 10 is 25% above median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Pharma-Bio Serv has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's Financial Strength compare to HCTI and BFRG?
Pharma-Bio Serv's Financial Strength of 10 can be compared against companies in the Healthcare Providers & Services industry. Historically, Pharma-Bio Serv's own Financial Strength has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Healthcare Providers & Services company?
A good Financial Strength depends on the Healthcare Providers & Services industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Pharma-Bio Serv and its competitors. Pharma-Bio Serv's current Financial Strength is 10, which is 25% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.59, compared to a current price of $0.47 — trading 20.4% below its estimated fair value. The current Financial Strength is 10, which is 25% above median its 10-year median of 8.00. Pharma-Bio Serv's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current Financial Strength is 10 as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.47 is trading 20.4% below its estimated GF Value™ of $0.59.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
Financial Strength: 10 (25% above median its 10-year median of 8.00)
GF Value™: $0.59 vs. price of $0.47 (20.4% below fair value)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
45GF Score
Get the complete analysis for PBSV
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
